Supporting information

Real-Time Label-Free Targeting Assessment and *In Vitro* Characterization of Curcumin-Loaded Poly-lctic*co*-glycolic Acid Nanoparticles for Oral Colon Targeting

Mohamed A. Akl,^{†,‡} Alma Kartal-Hodzic,[†] Teemu Suutari,[†] Timo Oksanen,[†] Isabella Monia Montagner,[§] Antonio Rosato,^{§,}[#] Hatem R. Ismael, [‡] Mohsen I. Afouna, [‡] Paolo Caliceti, [⊥] Marjo Yliperttula,^{†,⊥} Ahmed M. Samy, [‡] Francesca Mastrotto, [⊥] Stefano Salmaso, [⊥] and Tapani Viitala^{*,†,#}

[†]Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Finland

[‡]Department of Pharmaceutics and Ind. Pharmacy, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr City, Cairo, Egypt

[§]Veneto Institute of Oncology IOV-IRCCS, Padua, Italy

Department of Surgery, Oncology and Gastroentrology, University of Padova, Padova, Italy

¹Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy

KEYWORDS: curcumin, PLGA nanoparticles, colon cancer targeting, label-free, real-time, quartz crystal microbalance, surface plasmon resonance

Table 1SI. Kinetic parameters of the *in vitro* release profiles of curcumin from different C-PLGA NPs

 according to the Higuchi diffusion model.

| Formulation | Kinetic parameters | | | Type of fitted release | | |
|--------------|--------------------|----------------------|----------------------|------------------------|--|--|
| | R | k (h ⁻¹) | t _{1/2} (h) | Kinetics | | |
| C-PLGA | 0.974 | 13.4 | 13.9 | Diffusion | | |
| 1% CS-C-PLGA | 0.979 | 9.8 | 26.0 | Diffusion | | |
| WGA-C-PLGA | 0.928 | 13.8 | 13.1 | Diffusion | | |
| GE11-C-PLGA | 0.977 | 15.1 | 11.0 | Diffusion | | |

Table 2SI. Particle size (in nm) of different C-PLGA NPs stored in high purity water for up to 4 months at 4° C and RT (mean \pm SD, n = 3). RT = room temperature.

| Formula | T (°C) | Fresh | 1 st month | 2 nd month | 3 rd month | 4 th month |
|-----------------|--------|-------------|-----------------------|-----------------------|-----------------------|-----------------------|
| C-PLGA | 4°C | 220 ± 2 | 217 ± 1 | 233 ± 2 | 209 ± 2 | 245 ± 2 |
| | RT | 220 ± 2 | 221 ± 5 | 237 ± 8 | 214 ± 5 | 230 ± 1 |
| 0.25% CS-C-PLGA | 4°C | 245 ± 4 | 319 ± 20 | 325 ± 19 | 323 ± 2 | 335 ± 1 |
| | RT | 245 ± 4 | 306 ± 6 | $295\pm~6$ | 309 ± 5 | 323 ± 3 |
| 0.5% CS-C-PLGA | 4°C | 251 ± 3 | 365 ± 3 | 380 ± 10 | 399 ± 3 | 410 ± 4 |
| | RT | 251 ± 3 | 350 ± 12 | 363 ± 10 | 325 ± 2 | 380 ± 2 |
| 1% CS-C-PLGA | 4°C | 252 ± 3 | 247 ± 3 | 253 ± 2 | 249 ± 2 | 255 ± 2 |
| | RT | 252 ± 3 | 282 ± 2 | 283 ± 3 | 277 ± 5 | 288 ± 2 |
| WGA-C-PLGA | 4°C | 225 ± 2 | 217 ± 1 | 215 ± 3 | 215 ± 2 | 226 ± 1 |
| | RT | 225 ± 2 | 238 ± 3 | 233 ± 3 | 223 ± 2 | 209 ± 3 |
| GE11-C-PLGA | 4°C | 209 ± 2 | 207 ± 2 | 205 ± 4 | 209 ± 1 | 212 ± 1 |
| | RT | 209 ± 2 | 198 ± 4 | 197 ± 1 | 194 ± 2 | 199 ± 1 |

Table 3SI. Effect of SGF (A), SIF (B) and SCF (C) on particle size (in nm) and polydispersity index (PDI) of different C-PLGA NPs at 37 °C (mean \pm SD, n = 3). The different C-PLGA NPs were incubated in corresponding fluids for appropriate times for simulating GI-tract residence times.

| A | A | Effect (| Effect of SGF on the stability of different C-PLGA NPs | | | | |
|--------|------|-----------------|--|-----------------|-----------------|--|--|
| | | C-PLGA | 1% CS-C-PLGA | WGA-C-PLGA | GE11-C-PLGA | | |
| Fresh | Size | 220 ± 2 | 252 ± 3 | 225 ± 2 | 209 ± 2 | | |
| | PDI | 0.19 ± 0.02 | 0.13 ± 0.03 | 0.20 ± 0.01 | 0.14 ± 0.04 | | |
| 0.5 hr | Size | 201 ± 3 | 368 ± 5 | 197 ± 1 | 205 ± 4 | | |
| | PDI | 0.10 ± 0.01 | 0.34 ± 0.02 | 0.10 ± 0.10 | 0.11 ± 0.03 | | |
| 1 hr | Size | 209 ± 1 | 410 ± 24 | 197 ± 3 | 203 ± 2 | | |
| | PDI | 0.21 ± 0.02 | 0.32 ± 0.1 | 0.07 ± 0.02 | 0.10 ± 0.04 | | |
| 2 hr | Size | 201 ± 4 | 589 ± 28 | 208 ± 3 | 215 ± 1 | | |
| | PDI | 0.15 ± 0.01 | 0.44 ± 0.03 | 0.14 ± 0.01 | 0.17 ± 0.01 | | |

| I | 3 | Effect of SIF on the stability of different C-PLGA NPs | | | | |
|--------|------|--|-----------------|-----------------|-----------------|--|
| Fresh | Size | 220 ± 2 | 252 ± 3 | 225 ± 2 | 209 ± 2 | |
| | PDI | 0.19 ± 0.02 | 0.13 ± 0.03 | 0.19 ± 0.01 | 0.14 ± 0.04 | |
| 0.5 hr | Size | 234 ± 6 | 257 ± 2 | 207 ± 1 | 209 ± 2 | |
| | PDI | 0.29 ± 0.07 | 0.18 ± 0.03 | 0.14 ± 0.01 | 0.18 ± 0.02 | |
| 1 hr | Size | 233 ± 3 | 250 ± 4 | 204 ± 6 | 207 ± 2 | |
| | PDI | 0.35 ± 0.03 | 0.10 ± 0.02 | 0.16 ± 0.10 | 0.12 ± 0.10 | |
| 2 hr | Size | 242 ± 13 | 250 ± 2 | 207 ± 1 | 210 ± 7 | |
| | PDI | 0.34 ± 0.05 | 0.15 ± 0.1 | 0.13 ± 0.01 | 0.14 ± 0.1 | |
| 4 hr | Size | 239 ± 25 | 253 ± 1 | 198 ± 2 | 210 ± 5 | |
| | PDI | 0.33 ± 0.02 | 0.18 ± 0.02 | 0.08 ± 0.02 | 0.13 ± 0.1 | |
| 6 hr | Size | 243 ± 14 | 255 ± 7 | 197 ± 3 | 211 ± 3 | |
| | PDI | 0.37 ± 0.10 | 0.15 ± 0.03 | 0.08 ± 0.04 | 0.06 ± 0.03 | |

| (| 2 | Effect of SCF on the stability of different C-PLGA NPs | | | |
|--------|------|--|------------------|-----------------|-----------------|
| Fresh | Size | 220 ± 2 | 252 ± 3 | 225 ± 2 | 209 ± 2 |
| 1 ICon | PDI | 0.19 ± 0.02 | 0.13 ± 0.03 | 0.20 ± 0.01 | 0.14 ± 0.04 |
| 0.5 hr | Size | 224 ± 7 | 248 ± 4 | 213 ± 3 | 206 ± 1 |
| | PDI | 0.24 ± 0.03 | 0.17 ± 0.02 | 0.12 ± 0.01 | 0.18 ± 0.04 |
| 2 hr | Size | 237 ± 9 | 249 ± 3 | 211 ± 2 | 208 ± 3 |
| 2 111 | PDI | 0.24 ± 0.10 | 0.24 ± 0.05 | 0.14 ± 0.02 | 0.11 ± 0.02 |
| 6 hr | Size | 241 ± 3 | 258 ± 8 | 199 ± 4 | 208 ± 4 |
| | PDI | 0.24 ± 0.02 | 0.25 ± 0.02 | 0.14 ± 0.02 | 0.11 ± 0.06 |
| 24 hr | Size | 230 ± 6 | 280 ± 7 | 196 ± 2 | 201 ± 4 |
| | PDI | 0.25 ± 0.05 | 0.300 ± 0.02 | 0.22 ± 0.02 | 0.05 ± 0.01 |



Figure 1SI. *In vitro* release of curcumin from plain and functionalized C-PLGA NPs (mean \pm SD, n = 3). Simulated gastric fluid (SGF), simulated intestine fluid (SIF) and simulated colon fluid (SCF). A three-stage approach with three different pH release media was used in order to follow the recommendations on methods for dosage forms testing by US Pharmacopeia 36, as described earlier in reference 37. The media and time intervals used for the three different stages were the following: simulated gastric fluid (SGF; 0.2% NaCl, 0.2% pepsin, 0.7% hydrochloric acid, pH 1.2) between 1-2 h, simulated intestinal fluid (SIF; 0.68% KH₂PO₄, 3 mM sodium taurocholate, pH 6.8) between 3-5 h and simulated colonic fluid (SCF; PBS, pH 7.4) between 6-24 h. Vertical dashed and dotted lines marks the 2 h and 5 h time points, respectively.



Figure 2SI. Pig mucin (PM) binding to C-PLGA, 0.25% CS-C-PLGA, 0.5% CS-C-PLGA, 1% CS-C-PLGA, WGA-C-PLGA and GE11-C-PLGA NPs (mean \pm SD, n = 3).



Figure 3SI. Changes in SPR peak angular position (dashed lines) and TIR angular position (dotted line) measured with a laser wavelength of 785 nm as a function of time during interaction of A) curcumin

solution, B) noncoated C-PLGA NPs, C) chitosan coated CS-C-PLGA NPs, D) wheat germ agglutinin functionalized WGA-C-PLGA NPs and E) GE11 peptide functionalized GE-C-PLGA NPs with HT-29 cells. Solid lines represents the corrected SPR response curves, which were used for further analysis. The corrected SPR response curves were obtained by compensating for the difference in refractive index of the DMEM running buffer and the samples (i.e. diluted H₂O-based stock solutions of the NPs in DMEM) by subtracting the contribution of the TIR angular position changes from the corresponding changes in the main SPR peak angular position.